版本:
中国

BRIEF-Phase 3 Octave studies of oral tofacitinib in ulcerative colitis results published in the New England journal of medicine

May 3 Pfizer Inc

* Phase 3 Octave studies of oral tofacitinib in ulcerative colitis results published in the New England journal of medicine Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐